OpGen, Inc. (OPGN) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of OpGen, Inc. (NASDAQ:OPGN) in a research note published on Monday morning. They currently have a $1.00 target price on the medical research company’s stock.
A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered OpGen from a buy rating to a hold rating in a report on Saturday, August 26th. Dawson James reissued a buy rating on shares of OpGen in a report on Monday, June 19th.
OpGen (OPGN) opened at 0.30 on Monday. The stock’s market capitalization is $15.47 million. The stock’s 50 day moving average price is $0.32 and its 200-day moving average price is $0.83. OpGen has a 52-week low of $0.30 and a 52-week high of $3.10.
TRADEMARK VIOLATION WARNING: “OpGen, Inc. (OPGN) Earns Buy Rating from HC Wainwright” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/14/opgen-inc-opgn-earns-buy-rating-from-hc-wainwright.html.
In related news, CFO Timothy C. Dec bought 65,000 shares of the stock in a transaction dated Tuesday, July 18th. The shares were purchased at an average price of $0.40 per share, for a total transaction of $26,000.00. Following the completion of the purchase, the chief financial officer now directly owns 118,966 shares of the company’s stock, valued at $47,586.40. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Jven Capital, Llc bought 1,875,000 shares of the stock in a transaction dated Tuesday, July 18th. The stock was bought at an average price of $0.40 per share, for a total transaction of $750,000.00. The disclosure for this purchase can be found here. 53.27% of the stock is owned by corporate insiders.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. lifted its stake in OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the quarter. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 as of its most recent SEC filing. Institutional investors own 8.13% of the company’s stock.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.